2023 Was a tough year for the biopharma industry, with quite a few providers downsizing and restructuring their workforces to stay afloat. You can find indications of recovery, as mergers and acquisitions picked up through the pharmaceutical and lifestyle sciences business within the latter Component of 2023 and have continued https://sites.google.com/view/bio-sites/blog